Research Evidence / Overview of Studies for Elplat
Research Evidence in Stage III Colon Cancer (Adjuvant Setting)
This section summarizes the foundation of the evidence base for using Elplat after surgery, focusing on the large Randomized Controlled Trials (RCTs) and pooled analyses that were studied for long-term outcomes like Disease-Free Survival (time until recurrence) and Overall Survival (time until death from any cause).
The primary research for this condition was conducted through multiple, extensive Randomized Controlled Trials (RCTs) involving patients who had undergone complete surgical removal of the tumor. These studies monitored long-term outcomes such as the percentage of patients who remained free of recurrence (Disease-Free Survival) and long-term survival rates.
The large-scale research reported specific measurements of Disease-Free Survival and Overall Survival in the observed patient populations, with extended observation periods often tracked over five and even 10 years. Research has also explored the effect of different treatment durations, with studies comparing six months of therapy to a shorter three-month course.
What remains less clear is the data consistency when evaluating the specific survival outcomes related to this treatment duration for the overall patient population. The consistency of specific findings for the shorter duration, in particular, is an area where the data are less uniform across studies and patient subgroups. Evidence is also limited regarding the effect in specific lower-risk groups within Stage III disease.
Research Evidence in Advanced or Metastatic Colorectal Cancer
This part details the structure of the clinical research for the advanced stages of the disease, including studies that measured tumor shrinkage and the time until the disease worsened (Progression-Free Survival) across various treatment lines.
Research for metastatic disease was evaluated in numerous Randomized Controlled Trials (RCTs) that compared regimens containing Elplat to standard treatments available at the time. These studies examined key endpoints such as the time before the disease worsened (Progression-Free Survival) and the percentage of patients whose tumors shrank (Objective Response Rate).
The studies reported measurements of tumor shrinkage and Progression-Free Survival. Some research also explored reintroducing Elplat-based therapy after a break, with findings indicating specific tumor response measurements were observed in some studies in these later-line scenarios. In some early first-line trials, reported measurements for Overall Survival between the Elplat-containing regimen and the control regimen were not statistically distinguishable. This observation is related to the fact that many patients in the control group received Elplat as part of subsequent, later-line treatments, which makes the interpretation of the initial survival results complex.
Long-Term Research and Extended Follow-up
This summary focuses on the duration of observation in clinical research, outlining the availability of multi-year follow-up data from key trials and what is known about outcomes measured long after treatment completion.
The long-term outcomes associated with the use of Elplat were studied through extended follow-up periods in major Phase III trials for the adjuvant setting. Researchers monitored Overall Survival and the rates of disease recurrence many years after the initial treatment finished.
Research describes that long-term data for some large trials exist, with observation periods extending up to 10 years for patients treated in the adjuvant setting. These extended analyses also monitored the occurrence of long-term physical changes. For instance, research describes patterns related to the presence of residual sensory symptoms which were observed in some studies years after the completion of the medicine.
Evidence in Special Populations
This section will describe what the studies reported concerning specific patient groups, such as the available data for older adults (e.g., those aged 70 and above) and any research findings for individuals with certain comorbidities.
Studies explored the use of Elplat in various patient subgroups. Specifically, research examined the outcomes in older adults. Analyses of these trials show patterns related to tumor response rates being observed in older adults with metastatic disease. However, when monitoring Overall Survival measurements, findings were mixed across studies in this specific age group.
Evidence is limited for some patient groups. For instance, data for certain groups remain insufficient, particularly for patients with very advanced age (e.g., 75 years and older) or those with significant co-existing medical conditions.
What Remains Less Clear in the Research Landscape
This final section will synthesize the main uncertainties and limitations documented in the regulatory and scientific literature, including areas where data consistency is low or where more research is needed.
Research still contributes to the broader evidence landscape by highlighting areas where data are less consistent or where more research is needed.
The type of evidence varies across studies when analyzing the use of the medicine in later-line metastatic settings (third-line and beyond). This is because the evidence in these contexts is often derived from non-randomized studies where sample sizes were modest, and comparative evidence is lacking. Additionally, long-term effects in certain less common patient subgroups are not fully characterized. It is important to remember that findings describe group patterns, not personal outcomes, and the research does not determine whether an individual will respond similarly to the group findings.
